Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BR005-036C in Acute Migraine
NCT07792681Phase 3Recruiting
- Sponsor
- Brise Pharmaceuticals
- Start
- Sep 2026
- Primary completion
- Jun 2028
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of BR005-036C in migraine (3 arms), sponsored by Brise Pharmaceuticals. Primary endpoints: Percentage of Participants with Freedom from Pain at 2 hours and Percentage of Participants with Freedom from Most Bothersome Symptom at 2 hours. Started Sep 2026; status: recruiting.
02
Drugs
BR005-036C
03
Conditions
migraine
Beyond the preview
Go deeper on NCT07792681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07792681.